10 September 2015 New MTBVAC TB Study announced.

10 Sep 2015 - 18:15

On Tuesday 8 September 2015 researchers at the South African Tuberculosis Vaccine Initiative (SATVI) announced the roll out of a clinical trial to test MTBVAC i a live-attenuated derivative of  Mycobacterium tuberculosis. The vaccine, which has been previously tested in a phase I trial  in Switzerland, is intended as a BCG replacement vaccine.

Dr Michele Tameris

Principal Investigator

Research Bibliography

According to Dr Michele Tameris, the Principal Investigator from SATVI, the study would commence mid September  2015 and will be conducted over  a two year period where after the research findings will be published.

Tuberculosis remains a major global health problem and is responsible for infecting a third of the world’s population. In 2011 there were 8.7 million new cases of TB worldwide and 1.4 million people died from the disease. The only licensed TB vaccine is BCG which is over 90 years old. Although it protects against severe forms of paediatric disease BCG is of little or no protection against adult  lung TB, the main source of transmission of the epidemic.